Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 980 vs trastuzumab in HER2 positive early breast cancer
2012-004319-29Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abp 980 in breast cancer (2 arms), sponsored by Amgen. Primary endpoint: Pathologic complete response in breast tissue. Started Dec 2012; status: completed.
02
Drugs
abp 980
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-004319-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004319-29.